ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

ClinicalTrials.gov ID: NCT05649137

Public ClinicalTrials.gov record NCT05649137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes

Study identification

NCT ID
NCT05649137
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
512 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 3, 2023
Primary completion
Oct 27, 2024
Completion
Dec 12, 2024
Last update posted
Apr 26, 2026

2023 – 2024

United States locations

U.S. sites
23
U.S. states
9
U.S. cities
22
Facility City State ZIP Site status
Univ of Alabama Birmingham Birmingham Alabama 35222
Chambliss Clinical Trials, LLC Montgomery Alabama 36106
John Muir Physicians Network Concord California 94520
Velocity Clinical Research Westlake Los Angeles California 90057
Diablo Clinical Research, Inc. Walnut Creek California 94598
New West Physicians PC Golden Colorado 80401
ARS- Deland CRU DeLand Florida 32720
Jacksonville Ctr for Clin Res Jacksonville Florida 32216
Florida Inst For Clin Res LLC Orlando Florida 32825
Oviedo Medical Research, LLC Oviedo Florida 32765
Hope Clin Res & Wellness Conyers Georgia 30094
AMC Community Endocrinology Albany New York 12203
University of North Carolina Chapel Hill North Carolina 27514
PharmQuest Life Sciences LLC Greensboro North Carolina 27408
Amarillo Med Spec LLP Amarillo Texas 79106
Elligo Clin Res Centre Austin Texas 78704
Velocity Clin Res, Dallas Dallas Texas 75230
UT Southwestern Medical Center - Lingvay Dallas Texas 75390
PlanIt Research, PLLC Houston Texas 77079
DCOL Ctr for Clin Res Longview Texas 75605
Sugar Lakes Family Practice PA Sugar Land Texas 77479
National Clin Res Inc. Richmond Virginia 23294
Selma Medical Associates Winchester Virginia 22601-3834

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05649137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 26, 2026 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05649137 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →